AGC Biologics Capabilities Update June 2026: Cell Therapy

Navigating the complex journey of advanced therapies requires a delicate balance of deep technical expertise and manufacturing flexibility. Bridging the gap between early process development and commercial-scale GMP manufacturing demands robust strategies that can adapt to diverse cell types—including T-cells, hematopoietic stem cells, and mesenchymal stem cells.

A critical component of this evolution is the transition from traditional, manual open systems to fully automated, closed workflows. This shift minimizes contamination risks, enhances product consistency, and ensures compliance with rigorous global regulatory standards from the FDA and EMA. Supported by comprehensive in-house analytical testing for rapid quality control, developers can successfully de-risk transfer protocols for both autologous and allogeneic platforms. Discover how integrated solutions and innovative cleanroom concepts, like the dense floor model, optimize scalability and accelerate the delivery of life-changing therapies to patients worldwide.